In this phase 2 trial, patients with acute CHF, HTN (SBP >125) and mild-to-moderate renal insufficiency (GFR 30-75) were randomized to placebo or several doses of relaxin (human peptide that increases vasodilation and renal function). The relaxin group had improved dyspnea scores, shorter length of stay, and reduced CV death/CHF readmissions. Serious adverse events were similar between the groups. If confirmed in phase 3 studies, this will likely be a valuable addition to inpatient management of acute CHF (abstract).
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment